←
Aman Bhandari10,366 posts
Aman Bhandari avatar

Aman Bhandari

@GHideas

Former @WhiteHouse Tech Team, @CMSGov Sr. Research Scientist. Building Enterprise Data Science (#AI, #ML, #NLP). Boston Children's #DigitalHealth Advisory Board

◷ Joined June 2009▧ 269 Photos and videos
Pearl Freier avatar
⟳ Aman Bhandari retweeted
Pearl Freier@PearlF·11 Apr 2024

Look out for the ChatGPT wrapper SPAC masquerading as a TechBio company :)

ChatGPT wrappers have officially inundated the biotech startup scene. And it’s actually a bit sad that we aren’t investing in solving hard, long term problems.

Data & Society avatar
⟳ Aman Bhandari retweeted
Data & Society@datasociety·8 Apr 2024

Why the rush to use emerging, experimental AI technology in high-stakes settings? As Emily Tavoulareas writes, people and organizations are integrating LLMs and chatbots into their lives and work as if the technology is reliable — but it is clearly not. techpolicy.press/sure-no-one…

Chris Anderson (in London) avatar
⟳ Aman Bhandari retweeted
Chris Anderson (in London)@chr1sa·28 Mar 2024

This is true, and why AI doing the writing for you is intrinsically limited. The act of writing is the act of *thinking*. If you're not doing the writing yourself, the end product will be superficial and banal because the prompts were underthought

“You don’t imagine something first and then write it down. It’s through the act of writing that ideas make themselves known.” nautil.us/the-magic-of-the-b…

Ethan Mollick avatar
⟳ Aman Bhandari retweeted
Ethan Mollick@emollick·5 Apr 2024

This is a useful thread of recent papers showing that LLMs are biased when judging people in HR contexts. The papers offer some potential solutions, but it is important to recognize that current systems carry subtle biases that can be hard to recognize without extensive testing.

When evaluating the quality of resumes, ChatGPT shows signs of human biases. e.g. ChatGPT rates applicants with evidence of a disability as (all-else-equal) lower quality. But "this prejudice can be ... reduced by training custom GPTs on principles of DEI & disability justice."

Post attachment
Ethan Mollick avatar
⟳ Aman Bhandari retweeted
Ethan Mollick@emollick·5 Apr 2024

I have talked to a lot of executives buying Microsoft Copilot for their firms. Not one seems to have considered what it means to suddenly automate the vast majority of management writing without training or reconsidering the meaning of the work. From my book, Co-Intelligence:

Post attachmentPost attachmentPost attachmentPost attachment
Katie Bauer avatar
⟳ Aman Bhandari retweeted
Katie Bauer@imightbemary·18 Mar 2023

Scope is the enemy of proactivity on data teams. Proactivity is all about seeing what's happening and understanding what's coming next so you can be ready for it. The more things your team is responsible for, the more difficult this becomes.

Sarah Jabbour avatar
⟳ Aman Bhandari retweeted
Sarah Jabbour@SarahJabbour_·30 Mar 2024

I work on health-inspired AI, and often find it difficult to be taken seriously in the ML community (e.g., "you should submit to a more specialized venue"). This paper sums up my experience perfectly + highlights how beneficial application-driven ML can be to the field!

What drives innovation in machine learning? In a new paper, we argue that application-driven work is systemically under-valued in the machine learning community, but that it's essential for both innovation and impact. arxiv.org/abs/2403.17381 1/3

Post attachment
Vega Shah avatar
⟳ Aman Bhandari retweeted
Vega Shah@dr_alphalyrae·29 Mar 2024

Noticing an interesting trend in the world of techbio, where people with no research background say ‘when I worked in lab’ and they mean their one semester in a bio class. Never in my wildest dreams did i think the daily slog I did for 10+ yrs would become a desirable trait 😂

Pearl Freier avatar
⟳ Aman Bhandari retweeted
Pearl Freier@PearlF·27 Mar 2024

More from @LifeSciVC on AI: I think true generative AI—coming up with brand new molecules never before seen by man, I think that remains elusive. A lot of the discovery-focused AI shops are mining patent literature and adding methyl groups here and there to existing things—and that has value. But separating that from the sort of hype of, hey, we're going to turn a four year discovery process into four days & a computer and it's going to be great and we're going to be cranking out tons of drugs—I think that's just not borne out by history. Right? What was it the cover of Fortune magazine in 1981 was Merck’s new computer that was going to design drugs? And here we are, four decades later, and you know, we're still learning how to apply all this powerful computation to making new medicines. I'm a big fan of it. We put money where our mouth is on that. Starting Nimbus back in 2009 as a computer-focused drug company this, and every one of our companies has some version of that in its wheelhouse around AI and machine learning—big compute, Big Data, computer processing. I’m enthusiastic about it, you can't dismiss it. But I think a level of cautious optimism is required.

Pearl Freier@PearlF27 Mar 2024

Great conversation between Simone/@biocentury & Bruce/@atlasventure. On impact of AI on drug discovery/development, @LifeSciVC said: I think anyone today has to acknowledge the power of AI & machine learning to solve specific problems here. I do worry how far hype has gone beyond reality. There are clearly great opportunities to take large datasets— whether it's patient datasets, clinical datasets, and the like and apply AI & machine learning to them to identify patterns in there that might pick targets that might help you identify which patients are likely to respond.